Browsing by Author "Pooja Baweja"

Now showing 1 - 3 of 3

Angiotensin-converting enzyme inhibitory peptides and isoflavonoids from soybean [Glycine max (L.) Merr.]
(Frontiers Media S.A., 2022) Ayyagari Ramlal; Aparna Nautiyal; Pooja Baweja; Vikash Kumar; Sahil Mehta; Rohit Kumar Mahto; Shikha Tripathi; Aravindam Shanmugam; Bingi Pujari Mallikarjuna; Pushpa Raman; S.K. Lal; Dhandapani Raju; Ambika Rajendran
Angiotensin-converting enzyme I (ACE I) is a zinc-containing metallopeptidase involved in the renin-angiotensin system (RAAS) that helps in the regulation of hypertension and maintains fluid balance otherwise, which results in cardiovascular diseases (CVDs). One of the leading reasons of global deaths is due to CVDs. RAAS also plays a central role in maintaining homeostasis of the CV system. The commercial drugs available to treat CVDs possess several fatal side effects. Hence, phytochemicals like peptides having plant-based origin should be explored and utilized as alternative therapies. Soybean is an important leguminous crop that simultaneously possesses medicinal properties. Soybean extracts are used in many drug formulations for treating diabetes and other disorders and ailments. Soy proteins and its edible products such as tofu have shown potential inhibitory activity against ACE. Thus, this review briefly describes various soy proteins and products that can be used to inhibit ACE thereby providing new scope for the identification of potential candidates that can help in the design of safer and natural treatments for CVDs. Copyright © 2022 Ramlal, Nautiyal, Baweja, Kumar, Mehta, Mahto, Tripathi, Shanmugam, Pujari Mallikarjuna, Raman, Lal, Raju and Rajendran.
Harnessing heterosis and male sterility in soybean [Glycine max (L.) Merrill]: A critical revisit
(Frontiers Media S.A., 2022) Ayyagari Ramlal; Aparna Nautiyal; Pooja Baweja; Rohit Kumar Mahto; Sahil Mehta; Bingi Pujari Mallikarunja; Roshni Vijayan; Shukla Saluja; Vijay Kumar; Sunil Kumar Dhiman; S.K. Lal; Dhandapani Raju; Ambika Rajendran
Soybean is a predominantly self-pollinated crop. It is also one of the important oilseed legumes. Soybean is an excellent crop having industrial, traditional, culinary, feeding, and cultural roles. Genetic diversity in breeding programs is of prime importance as it ensures the success of any breeding by enhancing the outcomes and results of the plants. The phenomenon wherein the progeny exhibits greater biomass (yield) and a faster rate of development and fertility than its parents is referred to as heterosis. As of now, heterosis is mainly limited to the trait of seed yield and is considered the basis for the development of better (superior) varieties. Male sterility (MS) is extensively used for the production of seeds and the improvement of crops coupled with the traditional breeding programs and molecular technology. Therefore, deployment of MS and heterosis in breeding soybean could yield better outcomes. This review aims to focus on two aspects, namely, MS and heterosis in soybean with its scope for crop improvement. Copyright © 2022 Ramlal, Nautiyal, Baweja, Kumar Mahto, Mehta, Pujari Mallikarunja, Vijayan, Saluja, Kumar, Kumar Dhiman, Lal, Raju and Rajendran.
In silico analysis of angiotensin-converting enzyme inhibitory compounds obtained from soybean [Glycine max (L.) Merr.]
(Frontiers Media S.A., 2023) Ayyagari Ramlal; Isha Bhat; Aparna Nautiyal; Pooja Baweja; Sahil Mehta; Vikash Kumar; Shikha Tripathi; Rohit Kumar Mahto; Manisha Saini; Bingi Pujari Mallikarjuna; Shukla Saluja; S.K. Lal; Sreeramanan Subramaniam; Iten M. Fawzy; Ambika Rajendran
Cardiovascular diseases (CVDs) are one of the major reasons for deaths globally. The renin–angiotensin–aldosterone system (RAAS) regulates body hypertension and fluid balance which causes CVD. Angiotensin-converting enzyme I (ACE I) is the central Zn-metallopeptidase component of the RAAS playing a crucial role in maintaining homeostasis of the cardiovascular system. The available drugs to treat CVD have many side effects, and thus, there is a need to explore phytocompounds and peptides to be utilized as alternative therapies. Soybean is a unique legume cum oilseed crop with an enriched source of proteins. Soybean extracts serve as a primary ingredient in many drug formulations against diabetes, obesity, and spinal cord-related disorders. Soy proteins and their products act against ACE I which may provide a new scope for the identification of potential scaffolds that can help in the design of safer and natural cardiovascular therapies. In this study, the molecular basis for selective inhibition of 34 soy phytomolecules (especially of beta-sitosterol, soyasaponin I, soyasaponin II, soyasaponin II methyl ester, dehydrosoyasaponin I, and phytic acid) was evaluated using in silico molecular docking approaches and dynamic simulations. Our results indicate that amongst the compounds, beta-sitosterol exhibited a potential inhibitory action against ACE I. Copyright © 2023 Ramlal, Bhat, Nautiyal, Baweja, Mehta, Kumar, Tripathi, Mahto, Saini, Mallikarjuna, Saluja, Lal, Subramaniam, Fawzy and Rajendran.